Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
13 /100
LOW RISK
Score updated Jul 28, 2026

INDV — Indivior Pharmaceuticals, Inc. Dilution Risk Tracker

Track INDV dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track INDV — Get alerts when the score changes →

As of July 28, 2026, Indivior Pharmaceuticals, Inc. (INDV) has a DilutionWatch DilutionScore of 13/100, rated LOW dilution risk. Indivior Pharmaceuticals, Inc. has a market capitalization of $4.26B, 121.92M shares outstanding, 11 institutional holders tracked. Key dilution vectors include approximately 78 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
18
💰 Cash Runway
0
📊 Float Risk
7
⚠️ Warrant Exposure
15
🔄Convertible Debt

Dilution Forecast

☀️
Clear
No significant dilution signals
7%
🔁 Convertible Conversion 15%
• Convertible debt present: 9.8% potential dilution
🔔 Track INDV — Get forecast alerts →

Market Data

Market Cap$4.26B
Shares Outstanding121.92M
Float110.12M
Cash$175.00M
Debt$486.00M
Short InterestN/A

Institutional Holdings

QoQ: ↓ 73.6% shares (2026Q1 vs prior)
11 institutional holders · 33.31M shares
#1 BARCLAYS PLC 19.18M shares
#2 MORGAN STANLEY 10.00M shares
#3 GOLDMAN SACHS GROUP INC 3.25M shares
+ 8 more holders Sign up free to view →

Short Interest

Short Interest11.28M
Days to Cover7.6
% of Float10.2%
FINRA data as of Jul 15, 2026

Recent SEC Activity

4 INSIDER TRANSACTION 2026-03-17
8-K 8K EVENT 2026-03-17
4 INSIDER TRANSACTION 2026-03-13
8-K 8K EVENT 2026-03-13
4 INSIDER TRANSACTION 2026-03-11
Full SEC filing analysis available with free account

Recent News

No recent news

What This Means for INDV Shareholders

Indivior Pharmaceuticals, Inc. (INDV) has a DilutionScore of 13/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 28, 2026.

DilutionWatch's EDGAR monitoring for INDV shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for INDV in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch shows real-time score changes for INDV alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding INDV's Dilution Risk Factors

Key Insight

Although all scores use an inverted scale where higher numbers indicate greater risk, the company’s overall dilution exposure remains low due to strong cash reserves and minimal current issuance risks.

Primary Risk Drivers

The two highest-risk factors are Convertible Note Risk and Offering Ability. Convertible Note Risk scores at a level indicating significant potential for share dilution if notes convert into equity. This mechanism allows holders to exchange debt for shares, increasing the total number of outstanding shares. Offering Ability is also elevated, signaling that the company may be preparing to raise capital through new equity offerings, which could dilute existing shareholders.

Factors Currently Not a Concern

Float Risk and Warrant Exposure are both low, suggesting minimal near-term risk from public trading or warrant exercises. Float Risk reflects the proportion of shares available for trading; a low score indicates stable liquidity. Warrant Exposure shows limited exposure to potential future issuance through warrants. A change in either could become concerning if the company files new warrants or initiates a large-scale offering that increases float significantly.

SEC Filings to Watch

Key filings include S-3 registration statements, which signal plans for large equity offerings; 424B5 documents related to shelf registrations that may indicate upcoming capital raises; and 8-K Item 1.01 reports, which disclose material events such as new financing or convertible note conversions. Additionally, 10-Q quarterly reports should be monitored for any updates on debt obligations or changes in capital structure that might impact dilution risk.

How Dilution Happens

When convertible notes convert into shares, existing shareholders see their ownership percentage decrease unless they participate in the new issuance. Offering Ability increases share count through direct equity sales, while warrant exercises allow holders to purchase stock at predetermined prices, further diluting current holdings. Each of these mechanisms directly contributes to a higher total number of shares outstanding.

What Would Make This Worse

A significant deterioration in risk would occur if the company begins issuing convertible notes at scale or files multiple shelf registration statements, indicating readiness for large equity offerings. Additionally, if warrants are issued with low strike prices or if convertible notes are converted en masse, this could substantially increase share count and reduce per-share value, thereby worsening dilution exposure.

How to Monitor INDV for Dilution Risk

What This Risk Level Means

A dilution risk score of 35/100 for Indivior Pharmaceuticals, Inc. indicates a moderate level of concern, particularly for a large-cap operating company in the mid-cap range. While not immediately critical, this score signals potential vulnerabilities in the capital structure that could become problematic if not managed carefully. For a company of this size and type, dilution risk is especially concerning because it can affect investor confidence, stock performance, and long-term financial stability. The elevated convertible note risk factor highlights that the company has issued or is considering convertible securities that may convert into equity, thereby increasing the potential for share dilution.

What Typically Happens Next

Companies with this profile often proceed through capital-raising mechanisms such as shelf registrations, ATM programs, or warrant exercises. These actions are typically used to fund operations, reduce debt, or support growth initiatives. For a mid-cap operating company like Indivior, the likelihood of engaging in such activities increases if financial pressures arise or if strategic opportunities emerge. Monitoring for these filings is essential, as they often precede dilution events and can be identified through tools like Shelf & ATM Monitor.

Monitoring Playbook

To track Indivior effectively, use DilutionWatch to monitor score changes and key financial events. Set alerts for any increase in the dilution score above 20/100 or significant convertible note activity. Check the company’s filings monthly, with more frequent reviews during earnings seasons or when new capital-raising activities are announced. When thresholds are hit, assess whether the company is raising capital through equity or debt and evaluate how this impacts ownership concentration.

Early Warning Signals

Three key warning signals to watch for include: 1) A sudden rise in convertible note issuance or conversion activity, 2) The filing of a shelf registration that includes provisions for equity offerings, and 3) An increase in the number of warrants outstanding or their exercise prices declining. These indicators often precede material dilution events and should prompt immediate review.

What a Positive Resolution Looks Like

A positive shift in Indivior’s profile would occur if the company completes a capital raise that reduces reliance on convertible securities, pays down debt, or allows warrants to expire without exercise. A reduction in convertible note risk or an overall decline in the dilution score would also signal improvement. Additionally, any change in the company's capital structure that demonstrates increased financial stability and reduced equity issuance pressure would be a strong indicator of resolution.

Watch For

Any convertible note conversion events or shelf registration filings that could indicate upcoming equity issuance.

Full SEC filing analysis available with free account  →
Track INDV Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking INDV — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for INDV
INDV FDA Catalyst Timeline & Biotech Grade — BiotechSignsINDV Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.